Archive for the ‘Food and Drug Administration’ Category
Emergent Revises Upward 2010 Financial Forecast
Company anticipates total revenues of $275 to $300 million and net income of $40 to $50 million
ROCKVILLE, MD, July 20, 2010 – Emergent BioSolutions Inc. (NYSE:EBS) announced today that it is revising upwards its 2010 annual guidance to now reflect anticipated total revenues of $275 to $300 million and net income of [...]
In: Anthrax vaccines, Biothrax, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, Research and development, U.S. Food and Drug Administration, biotechnology · Tagged with: Anthrax vaccines, Biothrax, Emergent BioSolutions, Food and Drug Administration, Infectious disease, Strategic National Stockpile, United States, US government
Maryland Governor Martin O’Malley Leads Ribbon Cutting Ceremony at Emergent’s Baltimore Manufacturing Facility
ROCKVILLE, MD, July 16, 2010 – Emergent BioSolutions Inc. (NYSE:EBS) today held a ribbon cutting ceremony, led by Governor Martin O’Malley and Fuad El-Hibri, Emergent’s chairman and chief executive officer, to mark the formal opening of Emergent Manufacturing Operations [...]
In: Biothrax, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, Health Care, Management, Research and development, U.S. Food and Drug Administration · Tagged with: Chief executive officer, Emergent BioSolutions, Employment, Fuad El-Hibri, Martin O'Malley, Maryland, United States
Emergent BioSolutions Recognized as Biotechnology Firm of the Year by Tech Council of Maryland
ROCKVILLE, MD, May 13, 2010 – Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has been named Biotechnology Firm of the Year at the Tech Council of Maryland’s (TCM) Annual Tech Awards. This award acknowledges the company that best exemplifies the spirit of Maryland’s biotechnology community as well as its presence and leadership within the [...]
In: Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, Research and development, Tech Council of Maryland, U.S. Food and Drug Administration · Tagged with: Business, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, Research and development, Tech Council of Maryland
Emergent BioSolutions Chairman and CEO Fuad El-Hibri Recognized as Outstanding International Business Leader
ROCKVILLE, Md., Mar 11, 2010 (BUSINESS WIRE) — Emergent BioSolutions Inc. (EBS 15.96, -0.03, -0.19%) announced today that Fuad El-Hibri, its chairman and chief executive officer, has been named by the World Trade Center Institute (WTCI) as one of Maryland’s outstanding international business leaders. Celebrating the spirit of global ambition and excellence in international leadership, [...]
In: Business, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Management, U.S. Food and Drug Administration, biotechnology · Tagged with: Baltimore, Chief executive officer, Emergent BioSolutions, Fuad El-Hibri, Maryland
500 Most Influential Muslims: Science and Technology
The Prince Alwaleed Bin Talaal Center for Muslim-Christian Understanding and The Royal Islamic Strategic Studies Centre published its first edition in what promises to be an annual series of insight into the movers and shakers of the Muslim world. Entitled The 500 Most Influential Muslims 2009, the book categorizes Muslims’ influential capacities into 15 [...]
In: Biothrax, Business, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri · Tagged with: Emergent BioSolutions, Muslim world, United States, Washington DC.
Fuad el-Hibri, king of anthrax, wins an award from Ernst & Young
Marie-José Daoud
Awarded the Ernst and Young prize for Entrepreneur of the year 2009 in the Technology category for the Greater Washington region last June, Fuad El-Hibri is the CEO of Emergent Biosolutions, an American company that supplies the anthrax vaccine to the American government. He is in line for the national E&Y 2009 prize, which [...]
In: Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Management, Strategic National Stockpile, U.S. Department Of Health And Human Services, biotechnology · Tagged with: Emergent BioSolutions, Ernst & Young, Federal government of the United States, Food and Drug Administration, Porton Product, United States
Bad News Clouds Two Bio Defense Stocks
Written by Staff and Wire Reports
Tuesday, 08 December 2009 01:28
Key news developments will affect shares of these two companies who help meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons.
The two companies which waited until late after hours on Monday to announce [...]
In: Biothrax, Business, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, Management, Shareholders, U.S. Department Of Health And Human Services · Tagged with: BARDA, Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, Federal government of the United States, Fuad El-Hibri, Strategic National Stockpile, United States, United States Department of Health and Human Services
Emergent BioSolutions reacts to BARDA’s Request for Proposal cancellation
by Nick Rees on December 8, 2009
Fuad El-Hibri
The Office of the Biomedical Advanced Research and Development Authority has advised Emergent BioSolutions that while BARDA’s Request for Proposal has been canceled, Emergent is encouraged to submit a proposal for the office’s Broad Agency Announcement.
BARDA canceled the RFP for the procurement for rPA vaccines after [...]
In: Board of directors, Chief executive officer, Clinical trial, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, Leadership, Shareholders, U.S. Department Of Health And Human Services, biotechnology · Tagged with: Biotechnology and Pharmaceuticals, Chief executive officer, Emergent BioSolutions, U.S. Food and Drug Administration
Emergent BioSolutions Inc. (EBS) CEO & Chairman, 10% Owner Fuad El-hibri sells 15,000 Shares
CEO & Chairman, 10% Owner of Emergent BioSolutions Inc. (EBS) Fuad El-hibri sells 15,000 shares of EBS on 08/11/2009 at an average price of $16.78 a share.
EMERGENT BIOSULUTIONS INC. is a leading biopharmaceutical company dedicated to one simple mission – to protect life. EBS develops manufactures and commercializes vaccines and therapeutics that assist the body\’s [...]
In: Board of directors, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, Infectious disease, Shareholders, U.S. Food and Drug Administration · Tagged with: Anthrax, Anthrax vaccines, Emergent BioSolutions, Health, Infectious disease, Public health, U.S. Food and Drug Administration, Vaccine.
Emergent BioSolutions Inc., Q2 2009 Earnings Call Transcript
Emergent BioSolutions Inc., (EBS)
Q2 2009 Earnings Call
August 6, 2009 5:00 pm ET
Executives
Robert G. Burrows – Vice President, Investor Relations
Fuad El-Hibri – Chairman of the Board, Chief Executive Officer
R. Don Elsey – Chief Financial Officer
Daniel J. Abdun-Nabi – President, Chief Operating Officer
W. James Jackson, Ph.D. – Senior Vice President and Chief Scientific Officer
Analysts
Eric Schmidt [...]
In: Board of directors, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, Shareholders, U.S. Food and Drug Administration · Tagged with: Business, Chairman, Chief executive officer, Chief financial officer, Chief operating officer, finance, Investor relations, Vice president